Skip to main content
OpenTrials
Completed

NCT Number: NCT01716533

Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)

This study aims to 1) evaluate the C. difficile-specific immune response in CDI patients and 2) explore the difference in immune response between the patients with CDI recurrence and those with a sustained clinical response.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infections, Clostridium Difficile Bacterial Infections Bacterial Infections and Mycoses Clostridium Infections Gram-Positive Bacterial Infections Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

GSK Investigational Site, Hamilton, Ontario, Canada

Loading trial locations.

About this study

Patients with an initial episode of CDI will be followed up for CDI recurrence or sustained clinical response. The subjects will be allocated into 2 groups at the study end:

  • Recurrence Group: Subjects who experience recurrence of CDI after clinical response to antibiotic treatment to treat the initial CDI episode.
  • Sustained response Group: Subjects who do not experience recurrence of CDI after clinical response to the antibiotic treatment to treat the initial CDI episode.

This protocol has been amended twice to improve recruitment of subjects in the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol or/ and subjects who can receive assistance from his/ her legally acceptable representative (LAR) or a designate who can and will comply with the requirements of the protocol.
  • A male or female aged 18 years or older at the time of enrolment.
  • Written informed consent obtained from the subject/ LAR of the subject.
  • A reasonable prognosis of survival during the study period as judged by the investigator.
  • Outpatients, emergency room and/ or hospitalized subjects diagnosed with CDI for which the symptoms started maximum 14 days prior to study enrolment.
  • Subjects who receive or plan to receive antibiotic treatment to treat the CDI episode.

Exclusion criteria

  • Concurrently participating or planning to participate in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Previous CDI episode within the previous 6 months before study enrolment (except for up to ~25% of the subjects).
  • Chronic diarrheal illness such as, but not limited to, ulcerative colitis or Crohn's disease.
  • Planned surgery for CDI within 24 hours after study entry.
  • Previous vaccination against Clostridium difficile.
  • Having received a Clostridium difficile monoclonal antibody product(s) within the previous 3 months or planned administration during the study period.
  • Administration of immunoglobulins within the previous 3 months or planned administration during the study period.
  • Subject having any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of the subject participating in the study, would make it unlikely for the subject to complete the study, or would confound the results of the study.
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within the previous 6 months.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history.
  • Family history of congenital or hereditary immunodeficiency.
  • Major congenital defects.

Treatment and study plan

blood sampling

Procedure

Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.

Stool Sample Collection

Other

Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).

Primary outcomes

  1. Serum Anti-toxin A and Anti-toxin B Antibody Concentrations at Day 14

    Time frame: At Day 14

    Serum anti-toxin B antibody concentrations were expressed as Geometric Mean Concentrations (GMCs), as measured by the Enzyme Linked Immunosorbent Assay (ELISA) for the cut-off of equal to or above (≥) 100 EU/mL.

  2. Serum F2 C-terminal Anti-toxin B Antibody Concentrations

    Time frame: At Day 14

    Serum F2 C-terminal anti-toxin B antibody concentrations were expressed as Geometric Mean Concentrations (GMCs), as measured by ELISA for the cut-off of 13.16 EU/mL.

Secondary outcomes

  1. Serum Anti-toxin A and Anti-toxin B Antibody Concentrations at Day 0 and Day 72

    Time frame: At Day 0 and at Day 72

    Serum anti-toxin B antibody concentrations were expressed as Geometric Mean Concentrations (GMCs), as measured by ELISA for the cut-off equal to or above (≥) 100 EU/mL.

  2. Serum Neutralizing Anti-toxin A and Anti-toxin B Antibody Titers at Day 14

    Time frame: At Day 14

    Neutralizing antibody concentrations were expressed as Geometric Mean Titers (GMTs), as measured in an inhibition of cytotoxicity assay (toxin neutralization assays) for the cut-off of 2, expressed in 1/DIL unit, in which DIL is the sample dilution corresponding to 50% neutralization.

  3. Serum Neutralizing Anti-toxin A and Anti-toxin B Antibody Titers at Day 0, Within 10 Days After Recurrence and at Day 72

    Time frame: At Day 0, within 10 days after start of recurrent episode if any, and at end of follow-up (Day 72)

    Neutralizing antibody concentrations were expressed as Geometric Mean Titers (GMTs), as measured in an inhibition of cytotoxicity assay (toxin neutralization assays) for the cut-off of 2, expressed in 1/DIL unit, in which DIL is the sample dilution corresponding to 50% neutralization. This measure concerned only diarrhea recurrence. No CDI recurrence was considered as part of the Group Sustained Response.

  4. Number of Subjects With Clostridium Difficile Infection (CDI) Recurrence

    Time frame: From Day 0 to Day 72

    A CDI recurrence is defined as the development of a new episode of CDI following clinical response at the end of standard of care (SoC) for the initial CDI episode.

  5. CDI Initial Episodes Severity Characteristics, in All Subjects

    Time frame: At Day 0

    Severity characteristics were expressed in duration of days for hospitalization, intensive care unit, Standard of Care (SoC) and CDI episodes.

  6. Number of Subjects With Initial CDI Episode by Severity, in All Subjects

    Time frame: At Day 0

    Initial CDI episodes were recorded by severity criteria: medical attention given, admission to intensive care unit, colectomy, death, high white blood cells (WBC) count, high creatinine count, hypotension/shock, clinical response to Standard of Care (SoC).

  7. Number of Subjects With CDI Recurrence by Severity, in Those Subjects Who Recur

    Time frame: At recurrence (within 10 days of start diarrhea) during a follow up period of up to 72 days per participant

    A CDI recurrence is defined as the development of a new episode of CDI following clinical response at the end of standard of care (SoC) for the initial CDI episode. An episode of diarrhea was not considered as a recurrence of CDI if the stool was negative for C. difficile or if the diarrhea was attributed to another cause than C. difficile. The severity criteria for CDI recurrent episodes were categorized into non-severe and severe.

  8. Number of Subjects With Failure of Antibiotic Treatment

    Time frame: Within 3 months before the initial CDI episodes

    Failure of antibiotic treatment against C. difficile is defined as the persistence or the incomplete resolution of symptoms (more than one unformed stool per day) after a full course of antibiotic(s) therapy (minimum 7 days).

    Aminopen+BetaLactam Inhib,1st Gen.Cephalosporin = Aminopenicillin+Beta-Lactamase Inhibitor and 1st Generation Cephalosporin.

    Aminopen+BetaLactam Inhib, 3rd Gen.Cephalosporin = Aminopenicillin+Beta-Lactamase Inhibitor and 3rd Generation Cephalosporin excluding Ceftazidime and Fluoroquinolone.

    Aminopen+BetaLactam Inhib and Fluoroquinolone = Aminopenicillin+Beta-Lactamase Inhibitor and Fluoroquinolone.

    Antipseudom Pen+BetaLactam Inhib and Cephalosporin = Antipseudomonal Penicillin+Beta-Lactamase Inhibitor and 1st Generation Cephalosporin and 3rd Generation Cephalosporin excluding Ceftazidime and Fluoroquinolone and Glycopeptides (Iv).

    Antipseudom Pen+BetaLactam Inhib and Glycopeptides = Antipseudomonal Penicillin+Beta-Lactamase Inhibitor and Glycopeptides (Iv).

  9. Number of Subjects With Risk Factors Associated With the Initial CDI Episode

    Time frame: At Day 0

    Risk factors for CDI included factors in three main domains involving host factors (advanced age, impaired immune status, co-morbidities); increased exposure to C. difficile spores (longer length of stays, healthcare environment, infected roommates or hand carriage by personnel); and factors that disrupt the normally protective colonic microflora layer (antimicrobials, other medications or procedures).

    CDI episodes within 6 months: Protocol exclusion criteria for enrolment allowed up to maximum 25% of the planned subjects having a previous CDI episode within the previous 6 months.

    Antibiotic taken within 3 months: Antibiotic not prescribed to treat C. difficile taken within 3 months before the current CDI episode.

  10. Number of Subjects With Risk Factors Associated With the CDI Recurrence

    Time frame: At recurrence (within 10 days of start diarrhea) during a follow up period of up to 72 days per participant

    Risk factors for CDI included factors in three main domains involving host factors (advanced age, impaired immune status, co-morbidities); increased exposure to C. difficile spores (longer length of stays, healthcare environment, infected roommates or hand carriage by personnel); and factors that disrupt the normally protective colonic microflora layer (antimicrobials, other medications or procedures).

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Serological Study in Adult Subjects With Clostridium Difficile Infection

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Oct 30, 2012
Registry last updated
Jun 7, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.